Clarity Pharmaceuticals Ltd
Company Profile
Business description
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation products that improve treatment outcomes for people with cancer. Its products use the perfect pairing of copper isotopes, copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy, which deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers. Its core clinical-stage programs, SAR-bisPSMA, SARTATE and SAR-Bombesin, each contain a different targeting agent that binds to specific receptors that are present on different cancer cells. It operates as one segment Development of Radiopharmaceuticals in Australia and the United States.
Contact
4 Cornwallis Street
National Innovation Centre
Eveleigh
SydneyNSW2015
AUST: +61 292094037
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
100
Clarity Pharmaceuticals Ltd News & Analysis
stocks
The ASX’s most shorted stocks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.70 | 54.50 | 0.62% |
| CAC 40 | 7,803.33 | 73.64 | 0.95% |
| DAX 40 | 25,087.27 | 280.30 | 1.13% |
| Dow JONES (US) | 51,654.95 | 423.31 | 0.83% |
| FTSE 100 | 10,552.05 | 110.45 | 1.06% |
| HKSE | 24,211.35 | 425.56 | 1.79% |
| NASDAQ | 27,366.17 | 172.83 | 0.64% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,749.35 | 57.50 | 0.42% |
| S&P 500 | 7,811.54 | 46.18 | 0.59% |
| S&P/ASX 200 | 8,716.60 | 55.70 | 0.64% |
| SSE Composite Index | 3,813.79 | 1.89 | 0.05% |